Page last updated: 2024-10-30

mazindol and ADDH

mazindol has been researched along with ADDH in 3 studies

Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

Research Excerpts

ExcerptRelevanceReference
"Mazindol CR was efficacious in the treatment of adults with ADHD, with a large effect size, and was well tolerated, supporting the progression to phase III."2.87A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). ( Handal, N; Konofal, E; Mulligan, I; Newcorn, JH; Schmith, V; Wigal, SB; Wigal, TL, 2018)
"Mazindol has been proposed as a potential treatment of children with attention deficit/hyperactivity disorder (ADHD)."2.79Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. ( Benadjaoud, L; Jacqz-Aigrain, E; Kaguelidou, F; Konofal, E; Laouénan, C; Lecendreux, M; Mentré, F; Zhao, W, 2014)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wigal, TL1
Newcorn, JH1
Handal, N1
Wigal, SB1
Mulligan, I1
Schmith, V1
Konofal, E2
Zhao, W1
Laouénan, C1
Lecendreux, M1
Kaguelidou, F1
Benadjaoud, L1
Mentré, F1
Jacqz-Aigrain, E1
Turle-Lorenzo, N1
Maurin, B1
Puma, C1
Chezaubernard, C1
Morain, P1
Baunez, C1
Nieoullon, A1
Amalric, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)[NCT02808104]Phase 284 participants (Actual)Interventional2016-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for mazindol and ADDH

ArticleYear
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    CNS drugs, 2018, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants;

2018
Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Fema

2014

Other Studies

1 other study available for mazindol and ADDH

ArticleYear
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:2

    Topics: Animals; Antiparkinson Agents; Attention Deficit Disorder with Hyperactivity; Cognition; Corpus Stri

2006